Aigen Investment Management LP Takes Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Aigen Investment Management LP acquired a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 4,767 shares of the company’s stock, valued at approximately $216,000.

A number of other hedge funds also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Apogee Therapeutics in the third quarter worth about $71,000. Wexford Capital LP purchased a new position in shares of Apogee Therapeutics in the third quarter worth approximately $230,000. Intech Investment Management LLC bought a new stake in Apogee Therapeutics during the third quarter valued at approximately $300,000. Valence8 US LP purchased a new stake in Apogee Therapeutics during the third quarter valued at approximately $308,000. Finally, FORA Capital LLC purchased a new stake in Apogee Therapeutics during the third quarter valued at approximately $399,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Stock Performance

Shares of Apogee Therapeutics stock opened at $36.14 on Monday. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of -14.93 and a beta of 2.46. The stock has a 50 day moving average price of $38.92 and a 200-day moving average price of $46.90. Apogee Therapeutics, Inc. has a one year low of $29.10 and a one year high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.25). Sell-side analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on APGE shares. Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Wedbush restated an “outperform” rating and issued a $90.00 price target on shares of Apogee Therapeutics in a research report on Monday, March 3rd. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price objective on the stock. Finally, Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 target price on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $91.60.

Insider Buying and Selling at Apogee Therapeutics

In related news, Director Mark C. Mckenna purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was purchased at an average price of $49.54 per share, with a total value of $990,800.00. Following the completion of the purchase, the director now owns 20,000 shares of the company’s stock, valued at approximately $990,800. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Carl Dambkowski sold 4,540 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $48.76, for a total value of $221,370.40. Following the completion of the sale, the insider now owns 258,073 shares of the company’s stock, valued at $12,583,639.48. The trade was a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 53,735 shares of company stock valued at $2,247,762 in the last three months. Company insiders own 36.10% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.